# US 10,117,884 B2 · Processing of natural polysaccharides by selected non-pathogenic microorganisms and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,884 B2
- Document ID: US10117884B2
- Status: Granted
- Kind: B2
- Application number: 15/205,796
- Filed: 2016-07-08
- Published: 2017-06-22
- Granted: 2018-11-06
- Earliest claimed: 2007-05-11
- Assignees: Mannatech, Inc.
- Applicants: Mannatech, Incorporated
- Inventors: Robert A. Sinnott
- Web page: https://patentgrep.com/patent/US10117884B2

## CPC

- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A23L 29/206: of vegetable origin
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/736: Glucomannans or galactomannans, e.g. locust bean gum, guar gum
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/886: Aloeaceae (Aloe family), e.g. aloe vera
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- C12P 19/02: Monosaccharides (2-ketogulonic acid C12P7/60)
- C12P 19/04: Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- C12P 19/12: Disaccharides
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.

## Claims

### Claim 1

A method of making a dietary supplement comprising:
incubating one or more natural polysaccharides with a non-pathogenic probiotic bacteria in a bioreactor system under conditions that stimulate the processing by the non-pathogenic probiotic bacteria of the polysaccharides into reduced molecular weight polysaccharides;
processing the natural polysaccharides into reduced molecular weight polysaccharides by the non-pathogenic probiotic bacteria; and
preparing the dietary supplement after at least a portion of reduced molecular weight polysaccharides have been processed by the non-pathogenic probiotic bacteria.

### Claim 2 (depends on 1)

The method of claim 1, wherein the resulting reduced molecular weight polysaccharides are manufactured into a single dosage nutritional supplement.

### Claim 3 (depends on 1)

The method of claim 1, further comprising the steps of:
isolating the reduced molecular weight polysaccharides from the natural polysaccharides and the bacteria; and
preparing a dosage form comprising the reduced molecular weight polysaccharides.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of preparing a dosage form comprising the reduced molecular weight polysaccharides, the natural polysaccharides and the bacteria.

### Claim 5 (depends on 1)

The method of claim 1, further comprising the reduced molecular weight polysaccharides are loaded into a dosage form selected from powder, capsule, gelcap, tablet, effervescent tablet, liquid or gum.

### Claim 6 (depends on 1)

The method of claim 1, wherein the bacteria comprise at least one of Lactobacillus, Lactococcus, Streptococcus, Enterococcus, Leuconostoc, Acetobacter, Candida, Kluveromyces, Saccharomyces, Torula, Torulaspora, Debaryomyces, Zygosaccharomyces, Bacterioides, Bacillus, Bifidobacterium, Eubacterium, Peptostreptococcus, Ruminococcus and Pediococcus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the reduced molecular weight polysaccharides are obtained by processing at least one of acetylated mannans from Aloe vera, glucomannans, aloe glucomannan, konjac glucomannan, galactomannans, arabinogalactans, larch arabinogalactans, algal polysaccharides, fucoidans, fungal polysaccharides, fungal glucomannans, gum tragacanth, gum ghatti, xanthan gum, guar gum, and gum acacia.

### Claim 8 (depends on 1)

The method of claim 1, wherein the reduced molecular weight polysaccharides are isolated away from the bacteria, and the reduced molecular weight polysaccharides are loaded into a dosage form selected from powder, capsule, gelcap, tablet, effervescent tablet, liquid or gum.

### Claim 9 (depends on 1)

The method of claim 1, wherein the non-pathogenic probiotic bacteria are in a sustained release form.

### Claim 10 (depends on 1)

The method of claim 1, wherein the reduced molecular weight polysaccharides are heteropolysaccharides, homopolysaccharides or both.

### Claim 11 (depends on 1)

The method of claim 1, wherein the step of processing the natural polysaccharides into reduced molecular weight polysaccharides by the non-pathogenic probiotic bacteria comprises:
processing a first portion of the natural polysaccharides wherein the first portion of the natural polysaccharides are selected from at least one of aloe vera gel polysacharrides, glucomannans, aloe vera acetylated mannans, and aloe glucomannan, and
processing a second portion of the natural polysaccharides wherein the second portion of the natural polysaccharides are selected from at least one of konjac glucomannan, galactomannans, arabinogalactans, larch arabinogalactans, algal polysaccharides, fucoidans, fungal polysaccharides, fungal glucomannans, gum tragacanth, gum ghatti, xanthan gum, guar gum, or gum acacia.

### Claim 12 (depends on 11)

The method of claim 11, wherein the resulting reduced molecular weight polysaccharides are manufactured into a single dosage nutritional supplement.

### Claim 13 (depends on 11)

The method of claim 11, further comprising the steps of:
isolating the reduced molecular weight polysaccharides from the natural polysaccharides and the bacteria; and
preparing a dosage form comprising the reduced molecular weight polysaccharides.

### Claim 14 (depends on 11)

The method of claim 11, further comprising the step of preparing a dosage form comprising the reduced molecular weight polysaccharides, the natural polysaccharides and the bacteria.

### Claim 15 (depends on 11)

The method of claim 11, further comprising the reduced molecular weight polysaccharides are loaded into a dosage form selected from powder, capsule, gelcap, tablet, effervescent tablet, liquid or gum.

### Claim 16 (depends on 11)

The method of claim 11, wherein the bacteria comprise at least one of Lactobacillus, Lactococcus, Streptococcus, Enterococcus, Leuconostoc, Acetobacter, Candida, Kluveromyces, Saccharomyces, Torula, Torulaspora, Debaryomyces, Zygosaccharomyces, Bacterioides, Bacillus, Bifidobacterium, Eubacterium, Peptostreptococcus, Ruminococcus and Pediococcus.

### Claim 17 (depends on 11)

The method of claim 11, wherein the reduced molecular weight polysaccharides are isolated away from the pathogen-free probiotic bacteria, and the isolated polysaccharides are loaded into a dosage form selected from powder, capsule, gelcap, tablet, effervescent tablet, liquid or gum.

### Claim 18 (depends on 11)

The method of claim 11, wherein the non-pathogenic probiotic bacteria are in a sustained release form.

### Claim 19 (depends on 11)

The method of claim 11, wherein the reduced molecular weight polysaccharides are heteropolysaccharides, homopolysaccharides or both.